Achillion Pharmaceuticals reports that the FDA has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH … more

Achillion also reports preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14-day study of ACH-4471 for patients with C3 glomerulopathy (C3G) or immune complex-mediated membranoproliferative glomerulonephritis … more

Separately, announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc. … more